Company news

IceCure Medical Ltd. news in 2022

IceCure Medical Ltd.'s news releases, calls and decks from 2022, newest first.

View company

IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

December 22, 2022

IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

December 20, 2022

IceCure Medical Ltd. Announces Proposed Public Offering

December 19, 2022

IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results

December 18, 2022

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

December 5, 2022

IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights

December 4, 2022

IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

November 27, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

November 7, 2022

IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month

October 25, 2022

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

October 18, 2022

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil

October 10, 2022

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

August 28, 2022

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights

August 14, 2022

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

July 24, 2022

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

June 12, 2022

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

June 8, 2022

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights

May 17, 2022

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

May 10, 2022

IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology

April 26, 2022

IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results

January 30, 2022

Calls in 2022

Decks in 2022